106 search results for screening
Questions Included in the Request for Information: Access to Coverage and Care in Medicaid & CHIP
Screening, Diagnosis, and Treatment [EPSDT] qualified supports who transitions to other Medicaid, is the developer of authoritative information regarding cancer prevention, screening, diagnosis, treatment, larger increases in rates of colorectal cancer (CRC) screening than states that did not expand Medicaid, with CRC screening grew by 8.8 percentage points in very early adopters of expansion (from 42.3% to 51.1, 7, 2019. 11 Fedewa, SA, et al. Changes in breast and colorectal cancer screening after Medicaid
https://www.nccn.org/docs/default-source/oncology-policy-program/equity/cms-medicaid-access-rfi-draft.pdf?sfvrsn=a7b8537e_3December 2022 Summit Report
Purpose of the Summit Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient preferences, patient needs according to varying intersectional identities, barriers to accessing appropriate and affirming cancer screening and treatment. A landscape, Continuum from Screening through Survivorship Tuesday, December 5, 2023 For More Information: https
https://www.nccn.org/docs/default-source/oncology-policy-program/december-2022-summit-report.pdf?sfvrsn=94daf5e7_1NCCN_fact_sheet
of nearly every type of cancer, as well as key cancer screening and prevention topics, screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance to support
https://www.nccn.org/docs/default-source/news/nccn_fact_sheet.pdf?sfvrsn=e8bf8d9b_13(Reconciliation) NCCN Holds Twelfth Annual State Oncology Society Forum 2023
to biomarker testing and screening, as well as various levels of prior-authorization reform, and fertility, Carolina, Oklahoma). Cori Chandler of ACS CAN focused on the importance of biomarker screening and testing
https://www.nccn.org/docs/default-source/oncology-policy-program/(reconciliation)-nccn-holds-twelfth-annual-state-oncology-society-forum-2023.pdf?sfvrsn=4d6f3dd0_1Harmonized Guidelines
Breast Cancer Screening and Diagnosis Version 2.2024 Colorectal Cancer Screening
https://www.nccn.org/global/what-we-do/harmonized-guidelinesSubmission Request Form
- 1.2025 Breast Cancer Screening and Diagnosis - 2.2024 Cancer in People with HIV - 1.2025 Cancer, Colorectal Cancer Screening - 1.2024 Dermatofibrosarcoma Protuberans - 1.2025 Distress Management, Hodgkin Lymphoma - 4.2024 Kaposi Sarcoma - 1.2025 Kidney Cancer - 2.2025 Lung Cancer Screening
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formAt a Glance
screening and prevention topics. These are available online free of charge for non-commercial use. The 88, screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance to support
https://www.nccn.org/home/news/at-a-glanceNCCN's Response to S.689/H.1074 An Act Relative to Patient Access to Biomarker Testing to Provide Appropriate Therapy
, NCCN ® is a developer of authoritative infonnation regarding cancer prevention, screening, ® The NCCN Guidelines include biomarkers used for the purposes of diagnosis, screening, monitming
https://www.nccn.org/docs/default-source/oncology-policy-program/access/nccn-letter-of-support-ma-s-689h-1074.pdf?sfvrsn=14ea90dd_3NCCN's Response to National Coverage Analysis: Allogeneic Hematopoietic Stem Cell Transplantation (HSCR) for Myelodysplastic Syndromes (MDS)
regarding cancer prevention, screening, diagnosis, treatment, and supportive care that is widely, Imaging AUC™ include recommendations pertaining to cancer screening, diagnosis, staging, treatment
https://www.nccn.org/docs/default-source/oncology-policy-program/guidelines/final-nccn-response-to-hsct-for-mds-nca.pdf?sfvrsn=7f72eb51_3NCCN's Response to the Noridian Healthcare Solutions, LLC Proposed Local Coverage Determination (LCD) Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
prevention, screening, diagnosis, treatment, and supportive care that is widely used by clinical, and used for the purposes of diagnosis, screening, monitoring, surveillance, prediction
https://www.nccn.org/docs/default-source/oncology-policy-program/guidelines/final-nccn-response-noridian-lcd-dl-39594.pdf?sfvrsn=aab42c3f_3About the NCCN Guidelines for Patients
for the NCCN Guidelines for Patients: Breast Cancer Screening Digital Health Award Fall 2024
https://www.nccn.org/patientresources/patient-resources/about-the-nccn-patient-guidelinesNCCN_Oncology_Research_Program_Brochure
research collaborations between NCCN Member Institutions and industry in cancer screening, of the first lung cancer screening program in Antelope Valley. This initiative has touched many
https://www.nccn.org/docs/default-source/oncology-research-program-(orp)/nccn_oncology_research_program_brochure.pdf?sfvrsn=ebab0181_3Request for Information for Healthcare Access in the Public Health Emergency
prevention, screening, diagnosis, treatment, and supportive care that is widely used by clinical, increases in rates of colorectal cancer (CRC) screening than states that did not expand Medicaid. Between, screening grew by 8.8 percentage points in very early adopters of expansion (from 42.3% to 51.1, examining rates of breast and cervical cancer screening among low-income adults find similar gains, of these programs could help increase access to cancer screening, early detection and care at a larger scale
https://www.nccn.org/docs/default-source/oncology-policy-program/access/rfi-draft-for-healthcare-access-in-the-phe.pdf?sfvrsn=a7d205a9_3Request for Information for Healthcare Access in the Public Health Emergency (PHE)
prevention, screening, diagnosis, treatment, and supportive care that is widely used by clinical, increases in rates of colorectal cancer (CRC) screening than states that did not expand Medicaid. Between, screening grew by 8.8 percentage points in very early adopters of expansion (from 42.3% to 51.1, examining rates of breast and cervical cancer screening among low-income adults find similar gains, of these programs could help increase access to cancer screening, early detection and care at a larger scale
https://www.nccn.org/docs/default-source/oncology-policy-program/quality/rfi-draft-for-healthcare-access-in-the-phe.pdf?sfvrsn=5504caab_32021-State-Oncology-Society-Forum-Summary
Screening, Treatment, and Survivorship Laura Makaroff, DO, Senior Vice President, Prevention & Early, and subsequent public awareness campaign that endorsed the safe resumption of cancer screening and treatment, -related delays in cancer screening and treatment. Dr. Richardson discussed the CDC’s COVID-19 Home
https://www.nccn.org/docs/default-source/business-policy/2021-state-oncology-society-forum-summary.pdf?sfvrsn=1a14acee_2NCCN's Response to the Proposed Local Coverage Determination (LCD) Molecular Assays for the Diagnosis of Cutaneous Melanoma (DL 39479)
regarding cancer prevention, screening, diagnosis, treatment, and supportive care that is widely used, Guidelines NCCN develops authoritative information regarding cancer prevention, screening, that measure changes in genes or gene products and used for the purposes of diagnosis, screening
https://www.nccn.org/docs/default-source/oncology-policy-program/access/final-nccn-response-wps-cutaneous-melanoma-lcd-pdf-copy.pdf?sfvrsn=dcb1a7b9_3Recently Updated Guidelines
Screening Version 1.2025 Guidelines for Supportive Care Hematopoietic Growth Factors
https://www.nccn.org/guidelines/recently-published-guidelinesNCCN LGBTQ Health Equity Infographic
Asking patients about their preferences for treatment, pronouns, support system, etc. Asking patients about their fertility plans/wishes so they can be fully informed about treatment options available to them. Ensuring educational materials feature diverse representation. Receiving trauma-informed training for this specific population to reduce the likelihood of unintentionally retraumatizing patients during screening, examinations, etc. Providers Need to Create More Welcoming
https://www.nccn.org/docs/default-source/oncology-policy-program/nccn-lgbtq-health-equity-infographic.pdf?sfvrsn=c771d22d_1HERC Healthcare Full
as documented through the medical record or meeting notes. • Offers flexible hours for screening
https://www.nccn.org/docs/default-source/oncology-policy-program/herc-healthcare-full.pdf?sfvrsn=a35196bc_1HERC Healthcare Abbreviated
• Offer Flexible Hours for Screening and Treatment • Offer Representative Patient Navigators
https://www.nccn.org/docs/default-source/oncology-policy-program/herc-healthcare-abbreviated.pdf?sfvrsn=fa3b6f46_1